Literature DB >> 29389170

Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes.

Walter Roberts1, Sherry A McKee1.   

Abstract

Varenicline reduces drinking in people with alcohol use disorder, but little is known about the mechanisms underlying this effect. Varenicline targets α4β2 and α7 nicotinic acetylcholine receptors, which are associated with several cognitive functions such as working memory. Varenicline may improve drinking outcomes by enhancing cognitive functioning. The current manuscript reports on cognitive outcomes from a placebo-controlled, double-blind human laboratory experiment examining the effects of varenicline on drinking behavior (Verplaetse et al., 2016a). Participants were 55 adult heavy drinkers who met criteria for an alcohol use disorder. They were randomized to receive varenicline (1 mg/day, 2 mg/day) or placebo. They completed a baseline assessment of cognitive functioning (i.e., digits backward task, continuous performance task) before starting medication. After a medication titration period, they attended a laboratory session (post medication Day 8) where they completed the cognitive assessment battery and an alcohol-primed ad libitum drinking task. Blood was collected to measure plasma varenicline levels. Varenicline produced dose-dependent improvements in working memory. Although there was no significant effect of oral varenicline dose on response time on the continuous performance task, participants with higher levels of plasma varenicline showed greater improvement of reaction time (RT). Among participants receiving 2 mg/day varenicline, larger improvements in working memory were associated less drinking, although mediation analyses did not find a significant indirect effect. These findings suggest that varenicline can improve working memory above baseline levels in heavy drinkers. Varenicline may reduce rates of alcohol use by improving working memory. (PsycINFO Database Record (c) 2018 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29389170      PMCID: PMC5797996          DOI: 10.1037/pha0000161

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  43 in total

Review 1.  "Loss of control" in alcoholism and drug addiction: a neuroscientific interpretation.

Authors:  M Lyvers
Journal:  Exp Clin Psychopharmacol       Date:  2000-05       Impact factor: 3.157

Review 2.  Working memory span tasks: A methodological review and user's guide.

Authors:  Andrew R A Conway; Michael J Kane; Michael F Bunting; D Zach Hambrick; Oliver Wilhelm; Randall W Engle
Journal:  Psychon Bull Rev       Date:  2005-10

3.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Authors:  L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

4.  Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).

Authors:  J T Sullivan; K Sykora; J Schneiderman; C A Naranjo; E M Sellers
Journal:  Br J Addict       Date:  1989-11

5.  A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.

Authors:  George M Haig; Earle E Bain; Weining Z Robieson; Jeffrey D Baker; Ahmed A Othman
Journal:  Am J Psychiatry       Date:  2016-03-04       Impact factor: 18.112

6.  Effect of disulfiram on cognition, subjective response, and cortical-event-related potentials in nonalcoholic subjects.

Authors:  S C Peeke; A R Prael; R I Herning; W Rogers; N L Benowitz; R T Jones
Journal:  Alcohol Clin Exp Res       Date:  1979-07       Impact factor: 3.455

7.  Verbal working memory impairment in schizophrenia patients and their first-degree relatives: evidence from the digit span task.

Authors:  H M Conklin; C E Curtis; J Katsanis; W G Iacono
Journal:  Am J Psychiatry       Date:  2000-02       Impact factor: 18.112

Review 8.  Developing human laboratory models of smoking lapse behavior for medication screening.

Authors:  Sherry A McKee
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

9.  Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial.

Authors:  Andrea de Bejczy; Elin Löf; Lisa Walther; Joar Guterstam; Anders Hammarberg; Gulber Asanovska; Johan Franck; Anders Isaksson; Bo Söderpalm
Journal:  Alcohol Clin Exp Res       Date:  2015-09-28       Impact factor: 3.455

10.  Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study.

Authors:  Roel J T Mocking; C Patrick Pflanz; Abbie Pringle; Elizabeth Parsons; Sarah F McTavish; Phil J Cowen; Catherine J Harmer
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

View more
  5 in total

Review 1.  Prospects for pharmacotherapies to treat alcohol use disorder: an update on recent human studies.

Authors:  Mehdi Farokhnia; Brittney D Browning; Lorenzo Leggio
Journal:  Curr Opin Psychiatry       Date:  2019-07       Impact factor: 4.741

2.  Searching for Personalized Medicine for Binge Drinking Smokers: Smoking Cessation Using Varenicline, Nicotine Patch, or Combination Nicotine Replacement Therapy.

Authors:  Jesse T Kaye; Adrienne L Johnson; Timothy B Baker; Megan E Piper; Jessica W Cook
Journal:  J Stud Alcohol Drugs       Date:  2020-07       Impact factor: 2.582

Review 3.  Mobile alcohol biosensors and pharmacotherapy development research.

Authors:  Walter Roberts; Sherry A McKee
Journal:  Alcohol       Date:  2018-08-03       Impact factor: 2.405

4.  The effect of varenicline on mood and cognition in smokers with HIV.

Authors:  Morgan Thompson; Robert Schnoll; Katrina Serrano; Frank Leone; Robert Gross; Ronald G Collman; Rebecca L Ashare
Journal:  Psychopharmacology (Berl)       Date:  2020-01-14       Impact factor: 4.530

Review 5.  Brain Structure and Function in Recovery.

Authors:  Sara Jo Nixon; Ben Lewis
Journal:  Alcohol Res       Date:  2020-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.